Drug Development

SBP-101

SBP-101 is a proprietary polyamine licensed by Sun BioPharma, Inc. from the University of Florida in 2011.  SunBioPharma, Inc. intends to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.

Current Clinical Trials

A first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer is currently enrolling patients.

Completed Clinical Trials

The First-Time-in-Human Phase 1 study of SBP-101 in patients with pancreatic ductal adenocarcinoma has reached completion in Australia and the United States.  A dose-escalation phase is expected to precede an expansion phase at the Maximum Tolerated Dose.

Click here for more information regarding the First-Time-in-Human Phase 1 study of SBP-101 in Australia.

Click here for more information regarding in the First-Time-in-Human Phase 1 study of SBP-101 in the United States.